|
|
|
|
| LEADER |
00000cam a22000003i 4500 |
| 001 |
EBSCO_ocn995357154 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170728s2017 nyu ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OCLCO
|d EBLCP
|d OCLCF
|d AGLDB
|d IGB
|d AUW
|d BTN
|d MHW
|d INTCL
|d SNK
|d G3B
|d S8I
|d S8J
|d STF
|d D6H
|d N$T
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9781536121933
|q (electronic bk.)
|
| 020 |
|
|
|a 1536121932
|q (electronic bk.)
|
| 020 |
|
|
|z 9781536121780
|
| 035 |
|
|
|a (OCoLC)995357154
|
| 050 |
|
4 |
|a R850
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Advances in Medicine and Biology.
|n Volume 123 /
|c Leon V. Berhardt editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Science Publishers, Inc.,
|c 2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed August 22, 2017).
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Preface; Chapter 1; Cefaclor: Clinical, Biochemical, Analytical and Stability Aspects; Abstract; 1. Introduction; 1.1. Cephalosporin Generations; 1.2. Cefaclor; 1.2.1. Mode of Action; 1.2.2. Anti-Bacterial Activity; 1.2.2.1. Gram Positive Spectra; 1.2.2.2. Gram Negative Spectra; 2. Indications; 2.1. Respiratory Tract Infections; 2.2. Urinary Tract Infections; 2.3. Skin and Soft Tissue Infections (SSTIs); 2.4. Blood Stream Infections; 2.5. Intra-Abdominal Infections; 2.6. Other Indications; 2.7. Immune System; 3. Contraindications; 3.1. Warning and Precautions; 3.2. Renal Cleareance
|
| 505 |
8 |
|
|a 3.3. Pregnancy and Nursing Mother4. Side Effects and Adverse Effects; 4.1. Gastrointestinal Effects; 4.2. Hypersensitivity; 4.3. Hepatic Effects; 4.4. Blood Disorders; 4.5. Kidney Disorders; 4.6. Superinfection; 5. Drug-Drug Interactions; 6. Pharmacokinetics; 6.1. Absorption; 6.2. Distribution; 6.3. Metabolism; 6.4. Elimination; 7. Resistance; 8. Dosage; 9. Analysis of Cefaclor; 10. Stability of Cefaclor; 11. Sustained Release Cefaclor; Conclusion; References; Chapter 2; Microbial Responses and Resistance to Chloramphenicol; Abstract; Introduction; Antibiotic Activity of Chloramphenicol
|
| 505 |
8 |
|
|a Gene Mutations for Chloramphenicol ResistanceStress-Induced Mutagenesis; Chloramphenicol Exporters; Enzymatic Inactivation of Chloramphenicol; Chloramphenicol 3-O-Acetyltransferase; Chloramphenicol Application; Conclusion; References; Biographical Sketches; Chapter 3; Cetirizine: Indications, Contraindications and Adverse Effects; Abstract; Introduction; Chemistry; Pharmacodynamics; Pharmacokinetics; Absorption and Distribution; Metabolism and Elimination; Indications; Contraindications; Adverse Effects; Conclusion; References; Chapter 4
|
| 505 |
8 |
|
|a Alteration of Perforin Status Caused by Asbestos Exposure in CTL and NK CellsAbstract; 1. Introduction; 2. Perforin in NK Cell Line Continuously Exposed to Asbestos Fibers; 3. Perforin in CTLs; 3.1. Production of Perforin and Degranulation; 3.2. Granzyme B Production and CD45RA Negative Cells; 3.3. Perforin, CTLs and Asbestos Exposure; 4. Reduced Anti-Tumor Immunity in Other Immune Cells; 5. Summary; Acknowledgments; References; Chapter 5
|
| 505 |
8 |
|
|a Deregulation of Platelet-Derived Growth Factor (PDGF)-Dependent Cell Proliferation through Potentiated and Sustained Activation of (1-Integrin, Induced by Tenascin-C-Derived Peptide TNIIIA2Abstract; Abbreviations; 1. Introduction; 2. About Our Research; 2.1. Hyperstimulation of PDGF-Dependent Proliferation in Nontransformed Fibroblasts by Peptide TNIIIA2; 2.2. Pro-Adhesive Nature of TNIIIA2; 2.3. Molecular Mechanism Underlying Hyperstimulation of PDGF-dependent Cell Proliferation by TNIIIA2; 2.4. Physiological Relevance of TNIIIA2-Induced Hyperstimulation of Cell Proliferation
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Clinical medicine.
|
| 650 |
|
0 |
|a Biology.
|
| 650 |
|
2 |
|a Clinical Medicine
|
| 650 |
|
2 |
|a Biology
|
| 650 |
|
6 |
|a Médecine clinique.
|
| 650 |
|
6 |
|a Biologie.
|
| 650 |
|
7 |
|a biology.
|2 aat
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Biology
|2 fast
|
| 650 |
|
7 |
|a Clinical medicine
|2 fast
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1562837
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4938641
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1562837
|
| 994 |
|
|
|a 92
|b IZTAP
|
